# A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

> **NCT05934955** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1839100
- **DRUG:** Placebo matching BI 1839100

## Key facts

- **NCT ID:** NCT05934955
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-13
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-10-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934955, "A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05934955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*